Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04234022 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv9
  2. Primary and study completion dates: Feb 2026 to Dec 2027v8
  3. Primary and study completion dates: Dec 2025 to Feb 2026v7
  4. Primary and study completion dates: Dec 31, 2025 to Dec 2025v6
  5. Primary and study completion dates: Apr 1, 2023 to Dec 31, 2025
    • Start date: Oct 1, 2020 to Oct 22, 2021
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: May 1, 2020 to Oct 1, 2020
    • Collaborator revised
    v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 1, 2020 to May 1, 2020
    • Site details revised
    v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future. There is the need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.
Trial Details
NCT Number NCT04234022
Lead Sponsor The Royal Wolverhampton Hospitals NHS Trust
Collaborators: University of Wolverhampton
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov